On the heels of comedian Dave Coulier’s announcement of his tongue cancer diagnosis, experts are sharing what to know about the disease.

Coulier, 66, announced in a Tuesday interview that he has been diagnosed with early-stage P16 carcinoma, or oropharyngeal tongue cancer. 

“Oropharyngeal” refers to cancer that begins at the base of the tongue. The “P16” indicates that it is associated with HPV (human papillomavirus).

JAMES VAN DER BEEK IS IN ‘HEALING PHASE’ OF CANCER BATTLE

The news comes just months after the “Full House” star announced his battle with an aggressive form of non-Hodgkin Lymphoma. The tongue cancer is “totally unrelated” to that initial cancer, he told “Today” in the interview.

“I went in for a PET scan, just a routine check-up, and something flared on the PET scan,” Coulier said. “It turned out that I have P16 squamous carcinoma at the base of my tongue.”

The comedian had announced on April 1 that he was cancer-free following the non-Hodgkin Lymphoma diagnosis.

“To go through chemotherapy and feel that relief of whoah, it’s gone, and then to get a test that says, well now you’ve got another kind of cancer … it is a shock to the system,” he said.

Coulier shared that he will undergo a course of 35 radiation treatments.

What to know about tongue cancer

Tongue cancer can affect the front of the tongue (oral cavity) or the base/back of the tongue (oropharynx), according to the National Cancer Institute. Risk factors and prognosis can differ substantially depending on the location of the cancer.

In 2025, it is expected that there will be about 20,040 new cases of tongue cancer and approximately 3,270 deaths, the NCI states. (These numbers only include cancers that begin in the front two-thirds of the tongue.)

COLORECTAL CANCER DIAGNOSES SOAR AMONG YOUNGER ADULTS FOR ONE KEY REASON

When including all oral cavity and oropharyngeal cancers — which totals all mouth and throat cancers — the numbers rise to 59,660 new cases and about 12,770 deaths in 2025, per the American Cancer Society.

The overall five-year survival rate for tongue cancer is 71%.

Studies have shown that cases have been on the rise in the U.S. in recent years, affecting almost all age groups and races.

“The rise is linked to the dramatic rise of HPV,” Fox News senior medical analyst Dr. Marc Siegel told Fox News Digital. “It can metastasize, but the prognosis is 80% to 90% curable if it’s HPV-related.”

CLICK HERE FOR MORE HEALTH STORIES

George Semeniuk, M.D., a medical oncologist and hematologist at City of Hope in Newport Beach, California, agreed that tongue cancer is one of the fastest-rising head and neck cancers doctors are seeing.

“Early detection is critical,” he told Fox News Digital.

Warning signs and risk factors

Some of the earliest warning signs of tongue cancer include a persistent sore or ulcer on the tongue, pain when swallowing, a lump or changes in speech, according to Semeniuk.

“Anything that lasts longer than two weeks should be evaluated by a specialist,” he advised.

Siegel added, “Look out for a sore that won’t heal or difficulty swallowing. Show your doctor, ENT or dentist.”

Other common signs include a lump or thickening on the tongue; red or white patches on the tongue or lining of the mouth; persistent tongue, pain in the mouth, jaw or throat; and numbness or burning in the tongue, according to multiple health sources.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP  

Those affected may also notice difficulty chewing, swallowing or speaking, or unexpected bleeding in the area.

If the cancer has spread, the patient may notice a lump in the neck (from enlarged lymph nodes), ear pain (usually on one side), or stiffness or swelling of the jaw. 

The biggest risk factors for tongue cancer are tobacco use, heavy alcohol consumption and HPV, Semeniuk noted.

“We are also seeing increasing cases in younger adults who have never smoked, which underscores the role HPV can play,” he said. “People with long-standing mouth irritation, weakened immune systems or poor oral hygiene may also be at higher risk.”

Treatment and prognosis

The standard treatment for tongue cancer is largely dependent on the stage of the disease and where it is located, according to experts.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Treatment depends on the stage and location of the tumor, but often involves a combination of surgery, radiation therapy and, in more advanced cases, chemotherapy or targeted therapies,” Semeniuk said.

“At City of Hope, we also use minimally invasive surgical approaches and precision-guided therapies to preserve speech and swallowing whenever possible.”

Siegel noted that tongue cancer tumors tend to be more responsive to surgical resection, radiation and chemotherapy.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“Prognosis is significantly better when tongue cancer is diagnosed early. If detected at an early stage, cure rates can be quite high,” Semeniuk told Fox News Digital. 

“That’s why it’s so important for people to pay attention to changes in their mouth and seek care promptly. Regular dental visits and HPV vaccination are also important steps in lowering risk.”

Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.

The World Health Organization (WHO) has announced its official guidance on the use of GLP-1 drugs for treating obesity.

GLP-1 drugs are medications that mimic the natural hormone glucagon-like peptide-1 (GLP-1), which are most commonly used for type 2 diabetes and medical weight loss.

The first guideline, released on Dec. 1, aims to address the “growing global health challenge of obesity,” WHO wrote in a press release.

WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT

Obesity affects more than one billion people globally and was associated with 3.7 million deaths. The number of people with obesity is expected to double by 2030.

While GLP-1 medications were added to the WHO’s Essential Medicines List for managing type 2 diabetes in high-risk groups in September 2025, the new guideline adds two key “conditional recommendations” for people with obesity.

“GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity,” the first condition states.

“While the efficacy of these therapies in treating obesity and improving metabolic and other outcomes was evident, the recommendation is conditional due to limited data on their long-term efficacy and safety, maintenance and discontinuation, their current costs, inadequate health-system preparedness and potential equity implications.”

“Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care.”

The second condition allows “intensive behavioral interventions,” including healthy diets, regular physical activity and support from health professionals, to be offered to adults with obesity who are prescribed a GLP-1, as part of a “comprehensive approach.”

The price of health

In addition to the health impacts, the cost of obesity is projected to hit $3 trillion annually by 2030. The WHO’s guideline attempts to reduce “skyrocketing” health costs associated with management of the condition and other complications.

The WHO guideline emphasized the importance of fair access to GLP-1 therapies.

CLICK HERE FOR MORE HEALTH STORIES

“Without deliberate policies, access to these therapies could exacerbate existing health disparities,” they wrote. “WHO calls for urgent action on manufacturing, affordability and system readiness to meet global needs.”

Despite the “rapid expansion” of GLP-1 production, the health agency revealed that by 2030, these therapies are predicted to reach less than 10% of people who could benefit from them.

“The guideline calls on the global community to consider strategies to expand access, such as pooled procurement, tiered pricing and voluntary licensing among others,” WHO stated.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Dr. Tedros Adhanom Ghebreyesus, director-general of WHO, wrote in a statement addressing the guideline that obesity is a “major global health challenge that WHO is committed to addressing by supporting countries and people worldwide to control it, effectively and equitably.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Our new guidance recognizes that obesity is a chronic disease that can be treated with comprehensive and lifelong care,” he said. “While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms.”

The agency added that obesity is a “complex, chronic disease” that is a driver of other illnesses like cardiovascular disease, type 2 diabetes and some cancers.

While GLP-1 therapies alone won’t solve the obesity problem, these therapies represent the “first efficacious treatment option for adults,” WHO stated.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The organization stressed that obesity requires creating healthier environments to promote wellness and prevent obesity, protecting high-risk individuals through screening and early interventions and ensuring lifelong access to healthcare.